SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-286862
Filing Date
2023-12-01
Accepted
2023-12-01 09:04:58
Documents
14
Period of Report
2023-12-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d619524d8k.htm   iXBRL 8-K 24554
2 EX-99.1 d619524dex991.htm EX-99.1 31645
6 GRAPHIC g619524dsp1.jpg GRAPHIC 6117
  Complete submission text file 0001193125-23-286862.txt   196901

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stok-20231201.xsd EX-101.SCH 2880
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20231201_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20231201_pre.xml EX-101.PRE 11278
8 EXTRACTED XBRL INSTANCE DOCUMENT d619524d8k_htm.xml XML 3341
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 231457707
SIC: 2834 Pharmaceutical Preparations